Antares Pharma (ATRS) Receives Analyst Rating

Antares Pharma (ATRS) has an average broker rating of 1, which is interpreted as a Strong Buy, as rated by 3 equity analysts. Nonetheless, 3 analysts are positive on the stocks future and they recommend a Strong Buy on the stock. Ranking by Zacks Investment Research for Coach Inc is 2, which is also a Buy.

Antares Pharma (ATRS) : The highest level Antares Pharma (ATRS) is projected to reach is $3 for the short term and the lowest estimate is at $2. The consolidated price target from 3 rating analysts who initiate coverage on the stock is $2.67 and the possibility the share price can swing is $0.58.


Antares Pharma (NASDAQ:ATRS): After opening at $1.37, the stock dipped to an intraday low of $1.345 on Thursday. However, the bulls stepped in to buy at lower levels and pushed the stock higher. The stock touched an intraday high of $1.41 and the buying power remained strong till the end. The stock closed at $1.4 for the day, a gain of 2.94% for the day session. The total traded volume was 848,505. The stocks close on the previous trading day was $1.36.

Antares Pharma, Inc. (Antares) is a specialty pharmaceutical Company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies. The Company develops and manufactures for itself and with partners, pressure-assisted injectors, with and without needles, which allow patients to self-inject drugs. It has developed variations of the needle-free injector by adding a small shielded needle to a pre-filled, single-use disposable injector, called the Vibex pressure assisted auto injection system. This system is an alternative to the needle-free system for use with injectable drugs in unit dose containers and is suitable for branded and generic injectables. It has also developed a disposable multi-dose pen injector for use with standard cartridges.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.